Mycobacterium tuberculosis (Mtb) uses a complex 3 0 , 5 0 -cyclic AMP (cAMP) signaling network to sense and respond to changing environments encountered during infection, so perturbation of cAMP signaling might be leveraged to disrupt Mtb pathogenesis. However, understanding of cAMP signaling pathways is hindered by the presence of at least 15 distinct adenylyl cyclases (ACs). Recently, the small molecule V-58 was shown to inhibit Mtb replication within macrophages and stimulate cAMP production in Mtb. Here we determined that V-58 rapidly and directly activates Mtb AC Rv1625c to produce high levels of cAMP regardless of the bacterial environment or growth medium. Metabolic inhibition by V-58 was carbon source dependent in Mtb and did not occur in Mycobacterium smegmatis, suggesting that V-58-mediated growth inhibition is due to interference with specific Mtb metabolic pathways rather than a generalized cAMP toxicity. Chemical stimulation of cAMP production by Mtb within macrophages also caused down regulation of TNF-a production by the macrophages, indicating a complex role for cAMP in Mtb pathogenesis. Together these studies describe a novel approach for targeted stimulation of cAMP production in Mtb, and provide new insights into the myriad roles of cAMP signaling in Mtb, particularly during Mtb's interactions with macrophages.
Introduction
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB) and is responsible for 1.5 billion asymptomatic infections and 1.2 million deaths annually (WHO, 2016) . In addition, nearly 500,000 new cases of drug resistant TB infections are diagnosed each year, underscoring the pressing need to discover new and rapid treatments for TB. Recently, the specialized metabolism that Mtb employs to establish and maintain infections in mammals has emerged as a "druggable" weakness in Mtb (VanderVen et al., 2015) and compounds that modulate such pathways are promising therapeutic candidates to combine with frontline anti-TB drugs.
Mtb's success as a pathogen is dependent on its ability to sense and respond to dynamic environments within its human host at all stages of infection, from establishment of active or persistent latent infection through reactivation and transmission. Bacteria employ second messengers, such as 3 0 , 5 0 -cyclic AMP (cAMP), to convert extracellular signals into physiological responses. Upon activation, adenylyl cyclases (ACs) convert cellular ATP into cAMP, which allosterically binds downstream effector proteins to alter their functions (McCue et al., 2000; Bai et al., 2011; McDonough and Rodriguez, 2012) . The Mtb genome encodes up to 15 distinct ACs and the bacteria synthesize cAMP in response to environmental signals such as pH, fatty acids, bicarbonate or CO 2 , reviewed by Bai et al. (2011) and McDonough and Rodriguez (2012) . Bioinformatic analyses indicate that most of these ACs contain different combinations of functional protein domains, suggesting a capacity to integrate multiple activities with cAMP signaling in Mtb (McCue et al., 2000) . cAMPresponsive transcription factors Crp MT (Rv3676) and Cmr (Rv1675c) in Mtb regulate gene expression (Rickman et al., 2005; Gazdik et al., 2009; Stapleton et al., 2010; Knapp et al., 2015; Ranganathan et al., 2016) to control metabolism, pathogenicity, dormancy and stress responses (Rickman et al., 2005; Gazdik et al., 2009; Stapleton et al., 2010; Xu et al., 2011; Pelly et al., 2012; Hayden et al., 2013; Nambi et al., 2013; Choudhary et al., 2014; Knapp et al., 2015; Ranganathan et al., 2016) . In addition, elevated cAMP levels in Mtb can stimulate activity of the lysine acetyltransferase MtPat (Rv0998), which modulates the function of key metabolic enzymes via post-translational modifications (Xu et al., 2011; Hayden et al., 2013; Nambi et al., 2013) . Given the complex nature of cAMPmediated regulation of Mtb physiology it is expected that elevating cAMP levels in the bacterium will simultaneously perturb multiple pathways including mycobacterial metabolism and disrupt the bacterium's ability to properly sense and respond to its environment during infection.
Bacterial pathogens, such as Bacillus anthracis, Pseudomonas aeruginosa, Bordetella pertussis and Vibrio cholera, have evolved systems to modulate host immune responses by secreting toxins that perturb cAMP signaling in their respective host cells (De, 1959; Holmgren et al., 1973; Leppla, 1982; Engel and Balachandran, 2009 ). While Mtb has been shown to directly secrete cAMP that gains access to the cytosol of infected macrophages (Agarwal et al., 2009; Bai et al., 2009) , little is known about how this secreted cAMP modulates the physiology of the host cells during infection. Many processes in eukaryotic cells are also controlled by cAMP, and signaling specificity in these cells is known to occur in tightly regulated microdomains of proteins associated with membrane complexes or within subcellular compartments (Sayner et al., 2011) . In innate immune cells such as macrophages, cAMP regulates metabolism, intracellular trafficking and innate immune responses (Serezani et al., 2008) . Importantly, macrophages sense increases in cytosolic cAMP levels through protein kinase A (PKA) (Aronoff et al., 2005; Serezani et al., 2008) , which downregulates tumor necrosis factor alpha (TNF-a) production by the cell (Wall et al., 2009) .
The large number and diversity of ACs in Mtb complicates efforts to define specific cAMP signaling pathways and to assign functional roles of individual ACs during infection. Most understanding of mycobacterial ACs is based on studies from a subset of AC enzymes that have been purified and studied in vitro. One of the best-studied mycobacterial ACs is Rv1625c, a class-III AC that shares sequence similarity with mammalian integral membrane cyclases (McCue et al., 2000; Guo et al., 2001; Reddy et al., 2001) . Recent work described several small molecules, including V-58, that inhibit Mtb growth in macrophages and in media containing cholesterol (VanderVen et al., 2015) . Transposon insertions in the Rv1625c ORF confer resistance to V-58, suggesting that Rv1625c is required for the inhibitory action of V-58. Consistent with this idea, treating wild-type Mtb with V-58 stimulates cAMP production but the mechanism behind the putative V-58-dependent simulation of cAMP synthesis was not determined.
Here, we show that the small molecule V-58 directly activates AC Rv1625c and stimulates cAMP production in Mtb and Mycobacterium bovis BCG. Using "knock-in" approaches with M. smegmatis (Msm) and Escherichia coli we also established that AC Rv1625c is necessary and sufficient for production of cAMP in response to V-58. We further found that stimulating cAMP production in Mtb increased the levels of cAMP released from the bacteria when Mtb was grown in liquid culture and in macrophages. Importantly, chemical stimulation of cAMP production with V-58 in Mtb dampened TNF-a production in infected macrophages. Thus, this work sheds new light on the multiple roles of cAMP in Mtb biology and establishes V-58 as the first compound that directly stimulates a specific AC to produce cAMP in Mtb.
Results

V-58 rapidly induces cAMP production in Mtb
We first quantified the kinetics of cAMP production in live Mtb following V-58 treatment by measuring cAMP levels at 0, 1, 2, 5 and 25 h post compound addition in 7H12 broth supplemented with 100 lM cholesterol and 20 mM acetate (Fig. 1) . The acetate was included as an additional carbon source to support bacterial growth in this assay, as previously described (VanderVen et al., 2015) . We found that cAMP levels were 10-fold higher than mock treated cultures in the bacterial lysates harvested immediately following V-58 exposure, and they increased 80-fold to reach a maximal level within 2 h of treatment (Fig. 1A) . Mtb is known to secrete significant amounts of cAMP into the extracellular environment (Agarwal et al., 2009; Bai et al., 2009; Gazdik et al., 2009 ), so we also measured the amount of cAMP in the culture supernatants at each time point. Elevated levels of secreted cAMP were detected in the culture supernatant by 1 h post compound addition and continued to rise throughout the duration of the 25 h assay (Fig. 1B) .
Induction of cAMP production in Mtb by V-58 requires Rv1625c
We hypothesized that V-58 directly activates AC Rv1625c to induce cAMP production in Mtb, and tested this idea using both "knockout" and "knock-in" approaches in several bacterial species. Rv1625c deletion (DRv1625c) strains were generated in Mtb H37Rv and M. bovis BCG by insertion of a kanamycin resistance cassette into the Rv1625c ORF using homologous recombination (Supporting Information Fig. S1 ). Rv1625c and its ortholog in M. bovis BCG (MB1651c) differ at just two nucleotides and encode identical proteins, so we refer to both as Rv1625c for simplicity. These mutations were complemented by ectopically expressing a single integrated copy of Rv1625c with its native promoter (Mtb DRv1625c::Rv1625c) (Supporting Information Fig. S1 ).
cAMP levels were compared between wild-type Mtb, the Mtb DRv1625c mutant and the Mtb DRv1625c::Rv1625c complement strain following V-58 treatment. We observed that cAMP levels in wild-type Mtb increased >100-fold following 24 h of treatment with V-58, but the compound had no effect on cAMP levels in the Mtb DRv1625c mutant. The production of cAMP was restored in Mtb DRv1625c::Rv1625c, despite higher basal levels of cAMP in this strain (Fig. 2) . V-58 also induced cAMP production by M. bovis BCG and this required Rv1625c (data not shown).
Rv1625c is sufficient for V-58-induced cAMP production
We next tested the sufficiency of Rv1625c for V-58-induced cAMP production. Rv1625c was expressed in Msm, which lacks an Rv1625c homolog. Msm mc 2 155::Rv1625c, which expresses an integrated copy of the Rv1625c ORF from Mtb driven by its native promoter, produced >50-fold more cAMP following 24 h exposure to V-58, while cAMP levels in wild-type Msm were not affected by exposure to the compound (Fig. 3) .
To further test specificity of Rv1625c for V-58-induced cAMP production, we took advantage of the fact that E. coli encode a single AC gene (cya). We expressed the full-length Mtb Rv1625c ORF driven by the E. coli nfo promoter as the sole AC in cya deficient E. coli strain HS26 to generate strain HS26-1625 (cya 2 Rv1625c 1 ).
E. coli HS26-1625 produced cAMP only when V-58 was provided in the bacterial media (Fig. 4) . These results show that AC Rv1625c is necessary and sufficient for cAMP production in response to V-58 stimulation, and that simply overexpressing Rv1625c in E. coli does not elevate the cAMP levels.
V-58 directly interacts with Rv1625c
Having demonstrated that V-58 induces AC Rv1625c to produce cAMP, we sought to determine whether this H37Rv was grown for 5 days in 7H12 media with 0.2% acetate and 100 lM cholesterol, and then washed in 7H12 media to remove extracellular cAMP. The bacterial cells were resuspended in 7H12 0.2% acetate and 100 lM cholesterol, with either 0.1% DMSO (black) or 10 lM V-58 (gray). Aliquots of the cultures were removed at the indicated times and processed to quantify cAMP concentrations which were normalized to 10 8 CFU. Amount of cAMP found in the (A) cytoplasmic fraction; and (B) extracellular media (secreted fraction). The data shown are the means of two biologically independent experiments with the error bars as the standard deviation between experiments. *p 0.05, **p 0.005 as determined by unpaired two-tailed t-test.
activation was direct. Rv1625c is thought to function as a membrane-associated homo-dimer, with each monomer containing a catalytic domain and six transmembrane (TM) spans (Reddy et al., 2001) . Purification of full length, functional AC Rv1625c has not been reported, likely due to the high level of hydrophobicity imparted by the 12 TM spans in the dimer. To bypass the difficulties associated with purification of AC Rv1625c, we used saturation transfer double difference nuclear magnetic resonance (STDD-NMR) to evaluate the specificity of the interaction between AC Rv1625c and V-58 within intact cells (Claasen et al., 2005) . This approach is based on the NMR saturation transfer from a target (AC Rv1625c) to a ligand (V-58), which occurs when the ligand binds to the target possessing NMR saturated protons (Mayer and Meyer, 2001; Meinecke and Meyer, 2001; Claasen et al., 2005) .
STDD-NMR takes advantage of the observation that large molecular complexes or targets are invisible by solution NMR spectroscopy. However, ligand binding to the target affects the ligand's NMR spectrum due to the chemical exchange between free and bound states. The difference between two NMR spectra of the targetligand complex collected with and without target protons' saturation, the so-called saturation transfer difference or STD, allows us to identify binding between the target and ligand. This STD experiment can be performed not only with a purified target, but also with a protein target expressed in viable bacteria, provided the expressed target has access to the small molecule ligand (Claasen et al., 2005) . The use of whole cells was attractive to study AC Rv1625c-V-58 interactions because our biological assays indicated that AC Rv1625c is active when expressed in E. coli. To ensure that the STD NMR The effect of the V-58 treatment on cAMP production by Mtb DRv1625c was compared with wild-type Mtb and complemented strain Mtb DRv1625c::Rv1625c. Bacteria were grown in 7H12 0.2% acetate and 100 lM cholesterol and treated with 10 lM of V-58 (gray bars) or 0.1% DMSO (vehicle control, black bars) for 24 h. cAMP levels from within the (A) bacterial pellet, and (B) extracellular medium. (C) The total cAMP represents the sum of the cytoplasmic and secreted cAMP levels for each strain and treatment. The data shown are the means and the error bars represent the standard deviation of three biologically independent experiments. *p < 0.01, **p < 0.005, ***p < 0.001 as determined by unpaired two-tailed t-test.
signal of the compound was specific to the interaction with AC Rv1625c, the ST double difference, STDD-NMR was used. In this case, the difference between two STD-NMR spectra of V-58 with either E. coli HS26 containing an empty vector or HS26-1625 cells expressing the AC Rv1625c target, respectively, was determined.
V-58 is soluble in water and possesses a wellresolved proton NMR spectrum (Fig. 5A ). The V-58 STDD-NMR signals exhibited a dose response ( Fig. 5B and C) suggesting that V-58 specifically binds to AC Rv1625c within intact bacterial cells. The protons, which exhibit the STDD-NMR signal, defined the V-58 binding site against the receptor, which included two protons on the pyridine ring, labeled "H a " and "H c ," and the protons on the pyrimidine ring, "H b " (Fig. 5B and C) . The trendlines of the proton peak intensities for all three peaks were similar, suggesting that the protons define the same binding site. The STDD-NMR signal was not saturated at the solubility limit of V-58 (800 lM), suggesting that the compound may also bind to lower affinity sites on the receptor (Fig. 5C ).
Model for V-58 binding site in Rv1625c suggests mechanism of action
Together, our biological data indicate that V-58 directly activates AC Rv1625c. While the STDD-NMR data revealed interactions between V-58 and AC Rv1625c, the actual binding site(s) of the compound cannot be determined with this experimental approach. First, we ruled out the possibility of interactions between the TM domains of AC Rv1625c and V-58 being required for the activity of the compound by expressing in E. coli a truncated form of AC Rv1625c 212-443 that contains the soluble catalytic elements without the TM spanning Nterminus. As expected, V-58 stimulated AC Rv1625c in an E. coli cya strain to produce cAMP (Supporting Information Fig. S4 ) suggesting that the TM domains are not required for the activity of V-58.
We used computational modeling to predict the binding site of V-58 on Rv1625c. V-58 was modeled to bind deeply in one ATP-binding pocket in a reversed orientation of the dimer (Fig. 5D ), leaving the other ATPbinding pocket fully accessible to ATP. Modeled in a vacuum environment, with the dielectric constant set to 1, the interaction energy between V-58 and the protein homo-dimer is 2101 kcal/mol. This pose suggests a putative interaction between V-58 and one of the two active sites in AC Rv1625c. The pose presents the pyridine and pyrimidine rings of V-58 to be deeply buried within the ATP-binding pocket, which is consistent with the STDD-NMR data ( Fig. 5A and D) . The model also suggests a mechanism of action that parallels what has been described for forskolin, which binds the inactive catalytic pseudo-site in eukaryotic transmembrane ACs (tmACs) to increase the activity of the second (functional) catalytic site to stimulate cAMP production by these enzymes (Seamon et al., 1981; Barovsky et al., 1984) .
V-58 stimulates cAMP production in intracellular Mtb
V-58 was identified based on its ability to inhibit Mtb's growth within macrophages and Mtb has been shown to secrete cAMP into its host macrophages, so we examined the effects of V-58 treatment in a macrophage infection model. We quantified bacterial cAMP levels from intracellular bacteria and from macrophage lysates following V-58 treatment. For these studies, J774.16 murine macrophages were infected with either live (H37Rv or CDC1551) or heat killed (CDC1551) Mtb. We found that cAMP levels within live, but not heat-killed, Mtb were elevated in response to V-58 (Fig. 6A ). In addition, cAMP levels in the macrophage lysates increased over 10-fold in macrophages infected with live, but not heat-killed, Mtb upon treatment with V-58 (Fig. 6B) . Importantly, V-58 did not alter cAMP levels in uninfected macrophages, despite some sequence similarity between Rv1625c and eukaryotic tmACs (McCue et al., 2000) (Fig. 6B ). These observations are consistent with the secretion of bacterial-derived cAMP from V-58 treated Mtb into the macrophages.
Given that cAMP is known to regulate the immune effector function of macrophages, we measured TNF-a production by Mtb-infected murine macrophages following treatment with V-58 (Fig. 6C) . Infection with Mtb resulted in a marked elevation of TNF-a production by murine macrophages, as has been reported previously (Agarwal et al., 2009 ). However, V-58 addition significantly reduced the amount of TNF-a detected in the supernatants of Mtb-infected macrophage cultures (Fig.  6C ). This effect of V-58 on TNF-a production was dependent on the presence of intracellular Mtb, as V-58 treatment had no effect on TNF-a production by macrophage cells stimulated with the toll receptor agonist LPS (Fig. 6C ). In addition, the cell permeable cAMP analog 8-Br-cAMP was able to suppress TNF-a production by both Mtb-infected and LPS-treated macrophages, indicating that the suppression of TNF-a in this system is subject to regulation by cAMP (Fig. 6C ). This finding supports our hypothesis that the reduction in TNF-a production following V-58 treatment of Mtb infected macrophages is due to the excess cAMP produced by intracellular Mtb.
Elevated cAMP levels are not sufficient for growth inhibition
The initial report on V-58 determined that this compound could inhibit Mtb's growth on media containing cholesterol, but not on standard mycobacterial growth media that contains glycerol and OADC (VanderVen et al., 2015) . Catabolism of cholesterol by Mtb results in production of propionyl-CoA, a metabolite that is toxic to the bacterium if allowed to accumulate. While wild-type Mtb can grow robustly on propionate as a sole carbon source, Mtb strains that lack key enzymatic components of the methyl malonyl and methyl citrate metabolic pathways cannot grow on propionate and are attenuated for growth in murine infection models (Munoz-Elias and McKinney, 2005; Munoz-Elias et al., 2006; Savvi et al., 2008) . As cAMP has been implicated in mycobacterial metabolism of propionate (Hayden et al., 2013) , we tested whether V-58 inhibits Mtb's growth on propionate.
Mtb was grown in media that provided glycerol and OADC (Mycomedia), 100 lM cholesterol, 20 mM propionate or both 100 lM cholesterol and 20 mM acetate in the presence of either 10 lM V-58 or 0.1% DMSO as a vehicle control (Fig. 7A-D) . V-58 inhibited Mtb growth when either cholesterol or propionate was provided alone, but had no effect on Mtb growth with standard Mycomedia or cholesterol media supplemented with 20 mM acetate (Fig. 7) . The bacteriostatic effects of V-58 lasted for 7 days, after which the bacteria resumed replication in either cholesterol or propionate. Rv1625c was required for Mtb growth inhibition (Supporting Information Fig. S5 ), consistent with its role as V-58's target. In contrast, V-58 did not inhibit growth of Rv1625c-expressing Msm mc 2 155::Rv1625c on cholesterol, despite the production of high levels of cAMP by this bacterium. This result indicates that the inhibitory effects of V-58 on mycobacteria are both species and media specific (Supporting Information Fig. S3 ). We measured cAMP levels to determine whether growth inhibition correlated directly with high cAMP levels in Mtb, but found that it did not. cAMP levels were elevated in all Mtb samples after 7 days of V-58 treatment, including those in Mycomedia and cholesterol 1 acetate medium, which showed no growth inhibition (Fig. 8) . As it does in the presence of cholesterol, V-58 treatment inhibited growth of Mtb on propionate while stimulating production of cAMP (Fig. 7) . However, untreated Mtb also grew robustly on propionate (Fig.   Fig. 6 . V-58 stimulates intracellular Mtb to produce cAMP. J774.16 murine macrophages were infected with live Mtb H37Rv or CDC1551, and heat-killed CDC1551 were treated with either 0.1% DMSO (black bars) or 10 lM V-58 (gray bars). cAMP levels were quantified by RIA from the (A) intracellular bacteria and (B) macrophage lysates. The data shown are the means of two biologically independent experiments. Error bars represent the standard deviation between replicates. (C) Macrophages were infected with Mtb CDC1551 at the indicated MOI and treated with 10 ng/ml LPS, 250 lM 8-Br-cAMP or V-58 at the indicated concentrations for 18 h and supernatant TNF-a levels were determined by ELISA. Data are means of four biologically independent experiments and the error bars represent the standard deviation between experiments. Statistical significance was determined with a two-tailed unpaired t-test, *p 0.05, **p 0.005 and ****p 0.0001. 7C) despite having elevated levels of cAMP comparable with those of V-58-treated bacteria grown on other carbon sources (Fig. 8) . Interestingly, cAMP levels in the M. bovis BCG vaccine strain were not affected by propionate (Supporting Information Fig. S6 ). Together, these data indicate that the growth inhibition caused by V-58-mediated activation of AC Rv1625c in TB-complex bacteria depends on the carbon source, and that cAMP elevation alone is not sufficient for Mtb growth inhibition.
Discussion
Here we demonstrate that V-58 directly and specifically activates the mycobacterial AC Rv1625c, both when the bacterium is grown in liquid culture and during infection of murine macrophages. Like forskolin, which has been used extensively to define cAMP signaling pathways in eukaryotic cells, compounds such as V-58 that allow rapid, robust and specific AC activation have tremendous potential for elucidation of cAMP signaling pathways during Mtb infection, as well as for possible therapeutic applications. Prior studies of cAMP signaling in Mtb have been limited by the use of poorly absorbed cAMP analogs, such as dibutyryl-cAMP or 8-Br-cAMP, or ectopic expression of a constitutively active AC catalytic domain (Gazdik et al., 2009) . cAMP analogs are not practical for infection studies and they provide only a generalized non-physiologic source of cAMP that does Fig. 8 . Elevation of cAMP levels by V-58 is not carbon source dependent. Mtb H37Rv was grown in either Mycomedia, 7H12 100 lM cholesterol, 7H12 20 mM propionate or 7H12 100 lM cholesterol and 20 mM acetate in the presence of either 0.1% DMSO (black) or 10 lM V-58 (gray). cAMP levels were quantified by RIA at 7 days for each culture and normalized to 10 8 CFU, with bars representing the total cAMP produced (sum of cAMP in the bacterial lysate and extracellular medium). Data shown are means of two biologically independent experiments and the error bars represent the standard deviation. Statistical significance was determined with a two-tailed unpaired t-test, **p 0.005. not allow specific pathway analyses. While use of recombinant ACs provides a more specific and durable source of endogenous cAMP production, this approach requires the generation of specialized Mtb strains. Constitutive overproduction of cAMP in recombinant Mtb may also trigger feedback control mechanisms that limit the net increase in cAMP levels, while background expression levels from intermittent breakthrough of inducible promoters can lead to spurious results.
Forskolin is a plant derived diterpene compound that directly stimulates mammalian tmACs to produce cAMP (Seamon and Daly, 1986) . tmACs are multi domain proteins that fold to contain one true active site and a socalled pseudo site (Zhang et al., 1997) . Forskolin binding to residues in the pseudo-site allosterically increases the activity of the functional active site (Dessauer et al., 1997) . Rv1625c shares sequence homology with mammalian tmACs, but functions as a homo-dimeric protein comprised of two monomers which are thought to come together to form two active sites (Guo et al., 2001) . AC Rv1625c is activated by CO 2 , but the underlying mechanism has not been determined (Townsend et al., 2009) . Our molecular modeling, based on the STDD NMR data indicates a specific interaction between V-58 and Rv1625c and predicts that V-58 interacts with residue Rv1625c D300 in at least one of the active site pockets. Future studies are needed to determine whether allosteric binding of V-58 docking to this active site alters the activity of the remaining active site, as occurs with forskolin-mediated activation of eukaryotic tmACs. Alternative mechanisms, such as V-58-mediated stabilization of an active dimeric protein, also cannot be excluded and warrant further investigation. Structural and biochemical determination of V-58's mechanism of action will provide new insights into how AC Rv1625c is activated and the dynamics of cAMP signaling during Mtb infection.
These results confirm previous work demonstrating that V-58 inhibits Mtb's growth on cholesterol, but not on media containing acetate or glycerol (VanderVen et al., 2015) . Our new finding that V-58 also inhibits Mtb growth on propionate medium further suggests that V-58 specifically inhibits physiologically relevant metabolic pathways in Mtb. Cholesterol is an important nutrient for Mtb during infection, in both tissue culture and animal models of disease (Pandey and Sassetti, 2008; Lee et al., 2013) , and its catabolism generates propionylCoA, acetyl-CoA and pyruvate as secondary metabolites (Yang et al., 2009; Thomas et al., 2011; Griffin et al., 2012) . Accumulation of propionyl-CoA is toxic to the bacterium, and Mtb has evolved the ability to assimilate propionyl-CoA as an energy source through the methyl citrate cycle, or to use propionyl-CoA to synthesize branched chained cell wall lipids by the methyl-malonyl pathway (Munoz-Elias and McKinney, 2005; MunozElias et al., 2006; Savvi et al., 2008) . The Mtb cholesterol metabolic pathway is not present in humans and bacterial mutants defective in this pathway are attenuated in various infection models (Rengarajan et al., 2005; Chang et al., 2007; Pandey and Sassetti, 2008; Hu et al., 2010; WHO, 2016) . This suggests that chemically inhibiting this pathway will also attenuate Mtb virulence in vivo and supports the idea that cholesterol is a dominant nutrient for Mtb during infection. V-58-mediated inhibition of mycobacterial growth on propionate as well as cholesterol raises the possibility that it can inhibit multiple metabolic pathways in Mtb, further strengthening the investigative and therapeutic potential for this and similar compounds.
While the mechanism by which V-58 restricts Mtb's growth is not clear, its dependence on AC Rv1625c suggests a role for cAMP-mediated regulation of one or more of these pathways. The carbon source dependence of growth inhibition despite similar levels of V-58-induced cAMP production across all conditions argues against a model in which high levels of cAMP cause generalized toxicity. In addition, propionic acid stimulated levels of cAMP production in Mtb comparable with those caused by V-58 while supporting robust bacterial growth. The dramatic increase in cAMP production in the presence of propionic acid is independent of Rv1625c (data not shown), and did not limit the ability of V-58 to induce additional cAMP production by AC Rv1625c. Therefore, the cAMP induction on propionic acid likely occurs through activation of another, yet to be identified, AC.
The restriction of Mtb growth on propionate-containing media only in the presence of V-58 despite the elevated cAMP levels, suggests that the source of cAMP production can provide specificity by differentially impacting downstream effector functions. cAMP signaling specificity in eukaryotic cells is achieved largely by subcellular localization of ACs with effector proteins, but has not been addressed in bacteria. However, the large number of ACs in Mtb, and the importance of cAMP signaling to pathogenesis make cAMP signaling specificity a compelling question in Mtb and likely a fruitful area of future investigation.
This study also supports a connection between cAMP signaling and propionate metabolism in Mtb. Previous work has shown that cAMP indirectly regulates enzymes involved in propionate metabolism in M. bovis BCG (Nambi et al., 2013) . cAMP binding activates MtPat to acetylate and propionylate lysine residues of its downstream protein targets (Xu et al., 2011; Nambi et al., 2013) . One of these targets is the acetyl-coA synthase (ACS) Rv3667, which is required for generating propionyl-CoA from propionate (Nambi et al., 2013) . Acetylation or propionylation inactivates ACS, so cAMPmediated activation of MtPat could limit the accumulation of toxic propionyl-CoA by preventing the conversion from propionate. The dramatic increase in cAMP production by Mtb grown in the presence of propionic acid compared with glycerol ( Fig. 8 and Supporting Information Fig. S6A-C) is consistent with such a "protective" effect, although this remains to be tested. In contrast, cAMP levels in M. bovis BCG were not affected by propionic acid (Fig. S6D-F) , which is consistent with a prior report (Nambi et al., 2013) . The possibility that differences in propionate metabolism exist between Mtb and M. bovis BCG needs further study, particularly with respect to whether these differences reflect metabolic deficiencies in M. bovis BCG that contribute its attenuation.
This work establishes that V-58 and similar compounds can be used to probe the impact of selective activation of AC Rv1625c on both bacterial physiology, as well as during infection models to determine how bacterially derived cAMP affects host cells. The macrophage data indicate that Rv1625c is expressed during infection and that V-58 does not stimulate the host tmACs expressed by the murine macrophages (Fig. 6 ). These data also indicate that cAMP produced by AC Rv1625c following drug treatment is secreted into the host cell during infection, an activity that has only been previously reported for the AC Rv0386 (Agarwal et al., 2009; Gupta et al., 2017) .
Granulomas are a major pathologic barrier that limits immune cell recruitment and antibiotic diffusion (Dorhoi and Kaufmann, 2014; Prideaux et al., 2015) . Within a granuloma, Mtb is sequestered in a cholesterol rich (Kim et al., 2010) and hypoxic (Via et al., 2008) microenvironment that is thought to favor bacterial persistence (Russell et al., 2010) . During infection, granuloma macrophages produce TNF-a (Marakalala et al., 2016) , which drives tissue pathology and is required to form and maintain granulomas (Flynn et al., 1995) . While complete depletion of TNF-a exacerbates TB disease (Capuano et al., 2003; Lin et al., 2010) , high levels of TNF-a can also promote excess inflammation, pathology and tissue damage (Flynn and Chan, 2001 ). Paradoxically, depleting TNF-a synergizes with TB antibiotic therapy when co-administered in TB infection models (Subbian et al., 2011; Skerry et al., 2012) . It is thought that TNF-a depletion disturbs the granuloma architecture to promote enhanced antibiotic availability or disrupts the granuloma microenvironment to make TB antibiotics more effective (Subbian et al., 2011; Skerry et al., 2012) . It has long been known that TNF-a production by macrophages can be down regulated in response to high levels of cytosolic cAMP (Katakami et al., 1988) and it is also known that Mtb-derived cAMP modulates TNF-a production in macrophages (Roach et al., 2005; Agarwal et al., 2009) . Thus, stimulating cAMP overproduction in Mtb could be a novel strategy to reduce TNF-a levels specifically in the infected macrophages to enhance activity of current TB drugs. Future studies using small molecules such as V-58 will shed new light on Mtb's metabolism during infection while elucidating cAMP signaling pathways and evaluating the therapeutic potential associated with perturbing cAMP signaling in Mtb during infection.
Experimental procedures
Maintenance of bacterial strains and cell cultures
Wild-type Mtb H37Rv (ATCC 25618), CDC1551, M. bovis BCG Pasteur and Msm mc 2 155 were used where indicated. Rv1625c-deleted strains of Mtb H37Rv and M. bovis BCG were generated by using homologous recombination to replace a 512 bp region of the ORF with a kanamycin resistance cassette in each bacterial species, as described in the Supplementary Methods section. Deletions were verified by Southern analyses (Supporting Information Fig. S1 ) and the mutations were complemented by ectopic expression of a wild-type Rv1625c allele from Mtb using an integrative vector, pMBC490 (Supporting Information Table S1 ). Unless specified otherwise, all mycobacterial strains were grown under shallow standing conditions from single use aliquots (Purkayastha et al., 2002) . Middlebrook 7H12 medium contains 7H9 base, 0.1% casitone, 100 mM 2-morpholino-ethane-sulfonic acid (MES) pH 6.6) supplemented with 0.05% tyloxapol and carbon sources as indicated in the text (Cho et al., 2007) , while Mycomedia is comprised of Middlebrook 7H9 base supplemented with 0.2% glycerol, 10% OADC and 0.05% Tween-80 (Purkayastha et al., 2002) . E. coli CA8000 (wild-type) and the HS26 variant of the TP610 cya deficient strain (Hedegaard and Danchin, 1985) were grown at 378C in Luria broth (LB) with shaking at 200 rpm.
J774.16 murine macrophages were maintained and passaged twice weekly in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (Gibco), 5% NCTC109 medium (Gibco) and 1% nonessential amino acids (Gibco) as described previously (McDonough et al., 1993; Bai et al., 2009 ).
Quantification of cAMP levels
Unless otherwise indicated, Mtb cultures were grown for 5 days in 7H12 medium containing 100 lM cholesterol and 20 mM acetate prior to addition of 0.1% DMSO or 10 lM V-58. After 24 h of treatment the cells were pelleted by centrifugation, and the resulting supernatants were collected as the extracellular "secreted" fraction of cAMP. The bacterial pellets were resuspended in 50 mM Na-acetate (pH 6.2), and all samples were heated to 858C for 1 h to kill Mtb bacilli. The heat-killed bacterial pellets were then boiled for 5 m and allowed to cool before the bacterial debris was pelleted by centrifugation. The resulting cleared lysates were collected as the "cytoplasmic" fractions. cAMP levels in Small molecule activation of Rv1625c in Mtb 303 both fractions were measured by a competitive radioimmunoassay (RIA) using rabbit polyclonal antibodies specific to cAMP (provided by Dr. James Dias) and a [I 125 ]-tyrosinemethyl-ester cAMP analog (Perkin Elmer) as previously described (Steiner et al., 1972; Swift and Dias, 1987; Bai et al., 2009) . The cAMP levels were normalized to 1 3 10 8 colony forming unit (CFU) of bacteria for both secreted and cytoplasmic fractions in each sample. The "total" levels of cAMP for a given sample represent the summation of the cytoplasmic and secreted levels of cAMP for that treatment and strain. The presence of 0.1% DMSO in the mock controls was shown not to affect cAMP levels in Mtb (Supporting Information Fig. S7 ).
Rate of cAMP production and secretion following V-58 treatment
H37Rv was grown to an optical density of 620 nm (OD 620 ) of 0.5-1.0 in 7H12 with 0.1% acetate 100 lM cholesterol under shallow standing ambient conditions. The bacterial cells were pelleted before being washed and resuspended with 7H12 supplemented with 0.1% acetate and 100 lM cholesterol to remove accumulated extracellular cAMP. Two aliquots of H37Rv were transferred to separate flasks. DMSO was added to a mock treated culture at a final concentration of 0.1% and V-58 was added to 10 lM final concentration in the other, which was considered time 0. Samples from each culture were harvested for cAMP and measured for OD 620 at time 0, 1, 2, 5 and 25 h after starting the treatment. cAMP levels were determined for both the secreted and cytoplasmic fractions for each time point using the cAMP specific RIA described above. The presence of 0.1% DMSO in the mock controls was shown not to affect Mtb growth (Supporting Information Fig. S7 ).
Expression of Rv1625c in Cya-deficient E. coli for cAMP quantification
The E. coli EndoIV (nfo) promoter region was PCR amplified with primers KM1021 and KM1022 (Supporting Information Table S1 ), and ligated into the KpnI site of pACYC184 to generate the empty vector control plasmid pMBC529. The full-length Rv1625c ORF (KM974 and KM959, Supporting Information Table S1 ) was inserted into the HindIII site to express Rv1625c from the nfo promoter in E. coli. The TP610 strain of E. coli harboring the cya-610 mutation was graciously provided by Hedegaard and Danchin (1985) . The pMBC529 (vector control) and pMBC530 (Pnfo-Rv1625c) plasmids were transformed into this cyadeficient strain.
Both strains were grown overnight in LB with 35 lg/ml chloramphenicol under shaking ambient conditions at 378C. Wild-type E. coli was grown in LB without added drug. The cultures were then diluted to 0.02 OD 620 into LB and grown for 3 h, prior to being diluted to 0.02 OD 620 into LB and treated with either 0.1% DMSO (mock) or 10 lM V-58 for 18 h before the cultures were processed for the quantification of cAMP by RIA as described above.
STDD-NMR analysis of V-58 interaction with AC Rv1625c cya-Deficient E. coli expressing Rv1625c from plasmid pMBC530 or the empty vector pMBC529 were grown overnight in LB medium containing 35 lg/ml chloramphenicol, prior to being diluted 1:1000 and grown to 4 l total volume of each culture. The cells were pelleted and washed with 20 ml of NMR buffer (10 mM potassium phosphate, pH 6.5) prior to being flash frozen. The cells were resuspended in the NMR buffer containing 10% D 2 O to a final volume of 500 ll to a total OD 550 of 115, which corresponds to 2.3 3 10 10 cells/ml. V-58 dissolved in d6-DMSO was added to the cells at the specified concentrations and incubated on ice for 15 m before being transferred to an NMR tube. The concentration of d6-DMSO in each sample was adjusted to 8%.
STDD-NMR-spectra were collected as previously described (Claasen et al., 2005) by using a Bruker Avance 700 MHz spectrometer equipped with a z-gradient TXI cryoprobe. The on-resonance irradiation of the protein during the 1D STD NMR experiment was performed at a chemical shift of 4.2 ppm where no resonances of V-58 were present. Off-resonance irradiation was applied at 44 ppm. A sequence of Gauss shaped pulses with a strength of 86 Hz and a length of 50 ms separated by a 1 ms delay was applied for 2 s during selective presaturation of the protein.
All spectra were obtained at 298 K, with 2048 scans. The NMR data were processed and analyzed using Topspin 2.1 (Bruker). The area under each peak that exhibited a STDD-NMR signal was integrated with two widths, 0.004 ppm and 0.016 ppm, respectively, to estimate the dependence of the results on the random noise.
Modeling of AC Rv1625c cytoplasmic domain and ligand docking
Wild-type AC Rv1625c cytoplasmic domain monomer homology models were generated and structurally aligned to the two monomers in a mammalian AC head-to-tail hetero-dimer structure (PDB ID: 1U0H) (Mou et al., 2005) using the program FAST (Zhu and Weng, 2005) , to obtain head to-tail AC Rv1625c homo-dimer structures. The homology models were generated using the MODELLER program, version 9.64 with the DOPE (Shen and Sali, 2006) and GA341 (Melo et al., 2002) energy functions. The National Cancer Institute's online structure generator, which uses the CORINA program (Gasteiger et al., 1990) , was used to generate the initial ligand structure. This structure was docked into the following two Rv1652c homo-dimer model locations using Autodock Vina (Trott and Olson, 2010) : (a) the binding pocket overlaid with forskolin from the mammalian AC structure (PDB ID: 1U0H), (b) a region between the two putative ATP binding sites in the homodimer. After some adjustments, a final plausible pose for V58 had it restricted to one ATP-binding site, similar to the way that forskolin acts as a cyclase activator (Mou et al., 2005) . A molecular mechanics model for V58 was generated using PARAMCHEM and CGENFF (Vanommeslaeghe and MacKerell, 2012; Vanommeslaeghe et al., 2012) and the two final docked ligand models were generated using minimization and dynamics performed using CHARMM version c35b3 (Brooks et al., 1983 (Brooks et al., , 2009 ). The complete details about the adjustments, choices and procedures used for the docking and modeling are provided in the supporting information.
Quantification of cAMP levels within murine macrophages
Levels of cAMP within the macrophages and intracellular bacteria were measured as previously described . For this, macrophages were inoculated with the H37Rv or CDC1551 strains of Mtb at a multiplicity of infection (MOI) of 200 bacteria per cell for 2 h, after which the cells were rinsed three times with Dulbecco's modified PBS to remove extracellular bacteria. J774.16 medium with either 0.1% DMSO (vehicle control) or 10 lM V-58 was added to the appropriate wells for a 2 h treatment period. The cells were then rinsed three times with DPBS, lysed with 0.5% triton-x-100 and 0.5% sodium deoxycholate for 3 m. Lysates were diluted with Mycomedia, and centrifuged to pellet the intracellular bacteria. Supernatants were removed for cAMP measurements, and the bacterial pellets were resuspended in an equal volume of Mycomedia. A small portion of each resuspended pellet was used to determine the bacterial burden by CFU enumeration prior to processing the remainder for cAMP levels by RIA as described above.
Quantification of TNF-a production by murine macrophages J774.16 macrophages were cultured in 24-well plates as previously described (VanderVen et al., 2015) . Cells were seeded at 10 5 cells per well and were allowed to adhere overnight at 378C and 5% CO 2 prior to infection. The macrophages were infected with M. tuberculosis CDC1551 as previously described (VanderVen et al., 2015) at the indicated MOI. Following 2 h of infection, the cultures were washed twice with warm supplemented DMEM, replenished with the same medium containing 8Br-cAMP (Sigma) at the indicated concentrations, LPS 10 ng/ml (List Biological Laboratories), V-58 at the indicated concentrations, or DMSO vehicle control. At 18 h post-infection the culture supernatants were collected and used to quantify TNF-a levels by ELISA (eBioscience) following the manufacturer's instructions. Addition of 0.1% DMSO was shown not to affect TNF-a levels (Supporting Information Fig. S7 ).
Statistical analysis
Unpaired two-tailed t-tests were performed for experimental data sets containing values acquired from at least two biologically independent experiments, with p 0.05 being considered statistically significant.
